A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Chongqing University Cancer Hospital
Institut Paoli-Calmettes
Massachusetts General Hospital
Hoffmann-La Roche
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Nantes University Hospital
Pfizer
Merck Sharp & Dohme LLC
Compass Therapeutics
Emory University
Chang Gung Memorial Hospital
Sun Yat-sen University
M.D. Anderson Cancer Center
Icahn School of Medicine at Mount Sinai
OHSU Knight Cancer Institute
KU Leuven
Kestrel Therapeutics, Inc.
Canadian Cancer Trials Group
Fudan University
Sun Yat-sen University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sun Yat-sen University
Qianfoshan Hospital
Canadian Cancer Trials Group
Ohio State University Comprehensive Cancer Center
Revolution Medicines, Inc.
National Cheng-Kung University Hospital
Pfizer
Seagen Inc.
Alliance for Clinical Trials in Oncology
Centre hospitalier de l'Université de Montréal (CHUM)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University of Colorado, Denver
Sun Yat-sen University
Centre Leon Berard
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NRG Oncology
H. Lee Moffitt Cancer Center and Research Institute
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
The First Hospital of Jilin University
Centre Oscar Lambret